Laboratory Co. of America Holdings (NYSE:LH) Shares Sold by SFE Investment Counsel

SFE Investment Counsel decreased its holdings in Laboratory Co. of America Holdings (NYSE:LH) by 1.0% in the 4th quarter, Holdings Channel reports. The firm owned 28,489 shares of the medical research company’s stock after selling 290 shares during the period. Laboratory Co. of America accounts for about 1.4% of SFE Investment Counsel’s investment portfolio, making the stock its 27th biggest holding. SFE Investment Counsel’s holdings in Laboratory Co. of America were worth $6,533,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. AMF Tjanstepension AB grew its stake in shares of Laboratory Co. of America by 37.0% in the 3rd quarter. AMF Tjanstepension AB now owns 86,026 shares of the medical research company’s stock valued at $19,232,000 after purchasing an additional 23,221 shares during the last quarter. CWM LLC grew its position in Laboratory Co. of America by 41.0% in the 3rd quarter. CWM LLC now owns 7,107 shares of the medical research company’s stock valued at $1,588,000 after buying an additional 2,068 shares during the last quarter. Exchange Traded Concepts LLC increased its stake in Laboratory Co. of America by 1,962.5% in the 3rd quarter. Exchange Traded Concepts LLC now owns 990 shares of the medical research company’s stock valued at $221,000 after buying an additional 942 shares during the period. Swedbank AB increased its stake in Laboratory Co. of America by 12.0% in the 3rd quarter. Swedbank AB now owns 56,884 shares of the medical research company’s stock valued at $12,712,000 after buying an additional 6,089 shares during the period. Finally, Indiana Trust & Investment Management Co purchased a new position in Laboratory Co. of America during the 3rd quarter worth $136,000. Institutional investors and hedge funds own 95.94% of the company’s stock.

Insider Buying and Selling

In related news, CMO Amy B. Summy sold 3,672 shares of Laboratory Co. of America stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $238.91, for a total transaction of $877,277.52. Following the completion of the sale, the chief marketing officer now owns 4,318 shares in the company, valued at approximately $1,031,613.38. This trade represents a 45.96 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Der Vaart Sandra D. Van sold 1,000 shares of the business’s stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $239.42, for a total transaction of $239,420.00. Following the completion of the transaction, the executive vice president now directly owns 2,670 shares of the company’s stock, valued at $639,251.40. The trade was a 27.25 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 18,383 shares of company stock worth $4,408,373 in the last ninety days. Insiders own 0.85% of the company’s stock.

Analysts Set New Price Targets

LH has been the topic of several analyst reports. Jefferies Financial Group lifted their target price on shares of Laboratory Co. of America from $275.00 to $290.00 and gave the company a “buy” rating in a report on Thursday, February 6th. Evercore ISI raised Laboratory Co. of America from an “in-line” rating to an “outperform” rating and lifted their price objective for the company from $260.00 to $265.00 in a report on Tuesday, January 7th. Barclays cut their target price on Laboratory Co. of America from $271.00 to $260.00 and set an “equal weight” rating for the company in a research note on Friday, February 7th. StockNews.com raised Laboratory Co. of America from a “hold” rating to a “buy” rating in a report on Friday, February 7th. Finally, Robert W. Baird upped their price objective on Laboratory Co. of America from $282.00 to $289.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. Three research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Laboratory Co. of America currently has an average rating of “Moderate Buy” and an average target price of $265.31.

Laboratory Co. of America Stock Down 1.7 %

Laboratory Co. of America stock opened at $241.05 on Thursday. Laboratory Co. of America Holdings has a fifty-two week low of $191.97 and a fifty-two week high of $258.59. The firm has a market capitalization of $20.16 billion, a price-to-earnings ratio of 27.33, a price-to-earnings-growth ratio of 1.84 and a beta of 1.07. The stock’s fifty day moving average is $236.92 and its two-hundred day moving average is $230.55. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.30 and a current ratio of 1.44.

Laboratory Co. of America (NYSE:LH) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $3.45 EPS for the quarter, beating analysts’ consensus estimates of $3.40 by $0.05. Laboratory Co. of America had a net margin of 5.73% and a return on equity of 15.29%. Analysts predict that Laboratory Co. of America Holdings will post 15.96 EPS for the current fiscal year.

Laboratory Co. of America Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 12th. Stockholders of record on Thursday, February 27th will be paid a dividend of $0.72 per share. The ex-dividend date is Thursday, February 27th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.19%. Laboratory Co. of America’s dividend payout ratio (DPR) is 32.65%.

Laboratory Co. of America Company Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.